Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003694
Status:
COMPLETED
Last Update Posted:
2013-06-05
First Post:
1999-11-01
Brief Title:
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Study of Newly Diagnosed Patients With BCRABL Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine NSC 141633 and Low-Dose Cytarabine
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Combining more than one drug may kill more cancer cells
Detailed Description:
PRIMARY OBJECTIVES
I To estimate the hematologic and cytogenetic response rate of newly diagnosed patients with BCRABL chronic myelogenous leukemia CML treated with combined homoharringtonine omacetaxine mepesuccinate and low dose cytarabine
II To estimate the toxicity of these two drugs given in combination in a cooperative group setting
SECONDARY OBJECTIVES
I To assess duration of hematological response and incidence of hematological progression for all patients
II To assess duration of cytogenetic response in patients continuing protocol therapy beyond the initial nine months
III To use quantitative Southern blot monitoring of blood samples to monitor molecular response rates in patients entered onto CALGB treatment studies for CML
IV To compare quantitative Southern blot results of blood samples with marrow cytogenetics at the time of complete molecular response
V To use RT-PCR to monitor the frequency of residual disease in patients who have achieved a complete blood Southern blot and marrow cytogenetic response elimination of BCRABL positivity by Southern blot and absence of the Philadelphia chromosome by cytogenetics
OUTLINE
Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days Courses repeat every 28 days Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon Minor cytogenetic responders are switched to interferon and nonresponders are removed from therapy and given the option to switch to interferon
Patients are followed every 6 months for 10 years
I To estimate the hematologic and cytogenetic response rate of newly diagnosed patients with BCRABL chronic myelogenous leukemia CML treated with combined homoharringtonine omacetaxine mepesuccinate and low dose cytarabine
II To estimate the toxicity of these two drugs given in combination in a cooperative group setting
SECONDARY OBJECTIVES
I To assess duration of hematological response and incidence of hematological progression for all patients
II To assess duration of cytogenetic response in patients continuing protocol therapy beyond the initial nine months
III To use quantitative Southern blot monitoring of blood samples to monitor molecular response rates in patients entered onto CALGB treatment studies for CML
IV To compare quantitative Southern blot results of blood samples with marrow cytogenetics at the time of complete molecular response
V To use RT-PCR to monitor the frequency of residual disease in patients who have achieved a complete blood Southern blot and marrow cytogenetic response elimination of BCRABL positivity by Southern blot and absence of the Philadelphia chromosome by cytogenetics
OUTLINE
Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days Courses repeat every 28 days Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon Minor cytogenetic responders are switched to interferon and nonresponders are removed from therapy and given the option to switch to interferon
Patients are followed every 6 months for 10 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CALGB-19804 | None | None | None |
| U10CA031946 | NIH | None | httpsreporternihgovquickSearchU10CA031946 |